Onglyza Lawsuit – Heart Failure


Onglyza lawsuit imageAstraZeneca’s prescription medication Onglyza, used in the treatment of Type 2 diabetes, may cause an increase in certain cardiovascular events, and could even result in death. Onglyza received FDA approval on July 31st, 2009, and is used to help control high blood sugar in patients with Type 2 diabetes (who do not suffer from diabetic ketoacidosis).

The Food and Drug Administration (FDA) has recently raised the alarm regarding potential harm caused by Onglyza, a newer diabetes medication.

The FDA is investigating harmful effects caused by Onglyza and its sister medication Kombiglyze regarding an increased risk of heart failure.  One of the FDA’s panel members advised that the drug should be withdrawn from the U.S. market but the safety panel opted to recommend a warning be added to updated prescribing information.

This is not the first problem that “newer” antidiabetic medications have presented and it is not the first sign of trouble for Onglyza.  A 2013 study showed that medications that act in a similar fashion to Onglyza may also be linked to a higher than normal risk of pancreatic cancer.

Medications such as Onglyza are designed to improve the lives of patients who use them but in some cases, the medications end up causing more harm than good.  If you or a loved one has suffered medical injury after taking Onglyza, you may be eligible for compensation.

Patients who have been injured by other antidiabetic medication have claimed that:

  • The company manufactured a dangerous medication
  • The company failed to adequately warn the medical community and the public about possible dangers
  • The company improperly marketed medications
  • The company knew about the dangers and chose to market the drug anyway

Patients or family members have been eligible in some cases for damages related to medical costs, lost wages, pain and suffering, wrongful death, and punitive damages.  Each potential case of medical injury is unique and must be evaluated separately.  Filing a lawsuit is no guarantee of success but if you or a family member has been injured by Onglyza, you should have your case evaluated by a legal expert.

The FDA Votes to Increase Warnings on Onglyza Labeling

onglyza heart failure lawsuit thumbnailAn FDA panel voted in April 2015 to require AstraZeneca to place a warning on Onglyza labeling which would caution patients of a possible increased risk of heart failure. This decision came after reviewing the data from the SAVOR study, which involved 16,492 patients, 1,222 of whom reported a major cardiovascular event. In this study, AstraZeneca was required to show that Onglyza would not increase the risk of heart failure or other cardiovascular conditions by more than 30 percent. It was found that those patients taking Onglyza were found to have a 27 percent greater risk of hospitalization for heart failure than those in the control group. Despite the manufacturer meeting the required threshold, the FDA panelists noted that more information was necessary in order to determine the actual risk of death from all causes associated with Onglyza. Indeed, fourteen of the fifteen panelists voted in favor of placing a warning on Onglyza labeling, while one panel member voted to withdraw Onglyza from the United States market altogether.

Symptoms of heart failure may include:

  • Difficulty breathing
  • Swelling of hands, feet or ankles
  • Irregular heart rate
  • Fatigue
  • Persistent cough or wheezing

Getting the Help You Need

Patients with Type 2 diabetes can feel frustrated with their choices of drugs to treat their illness. If they take no drugs, they risk uncontrolled sugar levels, which bring a myriad of health complications, however some of the new diabetes drugs, such as Onglyza, may have serious and even fatal side effects. If you developed a heart failure after taking Onglyza, you may be eligible for financial compensation.

The Onglyza lawyers at Seeger Weiss LLP have the reputation and willingness to fight for our clients’ rights. If you suffered from heart failure after taking Onglyza, call our office today at 888-473-5034.

View Sources
  1. AstraZeneca, (2015), Onglyza Prescribing Information, AstraZeneca, Accessed on 27 July 2015
  2. AstraZeneca, (2015), Onglyza Medication Guide, AstraZeneca, Accessed on 27 July 2015
  3. AstraZeneca, (14 April 2015), FDA Advisory Committee reviews SAVOR outcomes study results for ONGLYZA® (saxagliptin) and KOMBIGLYZE® XR (saxagliptin and metformin HCI extended-release), AstraZeneca, Accessed on 27 July 2015
  4. Ault, A., (14 April 2015) FDA Panel Backs New Safety Warnings on Two Diabetes Drugs, Medscape, Accessed on 27 July 2015
  5. Barber, J., (10 April 2015), FDA staff suggest AstraZeneca's diabetes drug Onglyza linked to higher rate of death, FirstWord Pharma, Accessed on 27 July 2015
  6. Butler, A. E., et al., (2013), Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors, Diabetes, Accessed on 27 July 2015
  7. European Medicines Agency, (26 August 2013), Investigation into GL-1-based diabetes therapies concluded, EMEA, Accessed on 27 July 2015
  8. Food and Drug Administration (11 February 2014), FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR), U.S. Food and Drug Administration, Accessed on 27 July 2015
  9. Hirschler, B., (02 September 2013), Doctors get good and bad safety news on diabetes drugs, Reuters, Accessed on 27 July 2015
  10. McDougall, C., et al., (2011), Drugs for Diabetes: Part 5 DPP-4 inhibitors, British Journal of Cardiology, Accessed on 27 July 2015
  11. Perry, S, (10 June 2013), New generation of diabetes drugs raising more concerns, Minnesota Post, Accessed on 27 July 2015
  12. Scirica, B., et al., (03 October 2013), Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, New England Journal of Medicine, Accessed on 27 July 2015
  13. Staton, T., (09 April 2015), AZ's Onglyza has most to lose at FDA safety confab, analysts say, FiercePharma, Accessed on 27 July 2015